Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

If you ever find yourself staring down this venomous Texas dweller, be careful. Statistics strongly suggest that it's better ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

Summit Therapeutics (SMMT) stock plunges 35% a day after the FDA approval of partner Akeso's (AKESF) cancer drug, ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little ...

--(BUSINESS WIRE)--Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision ...